Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.
about
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agentsING proteins as potential anticancer drug targets.High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.Endothelial cell Bcl-2 and lymph node metastasis in patients with oral squamous cell carcinoma.Directed elimination of senescent cells by inhibition of BCL-W and BCL-XLMetronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiationCT perfusion can predict overexpression of CXCL8 (interleukin-8) in head and neck squamous cell carcinoma.Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effectsEstrogen regulation of apoptosis: how can one hormone stimulate and inhibit?Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma.The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones.Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule.AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.BCL2 suppresses PARP1 function and nonapoptotic cell death.B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity.TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis.Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission tomography.Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.Kaposi sarcoma-associated herpesvirus g protein-coupled receptor enhances endothelial cell survival in part by upregulation of bcl-2.Different forms of cell death induced by putative BCL2 inhibitors.Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database.Oncosuppressors and Oncogenes: Role in Haemangioma Genesis and Potential for Therapeutic Targeting.
P2860
Q30502341-A018D283-B933-42FE-9B3E-73104783AA8BQ33574029-48984B1D-4E58-413B-A80F-0DBB9303C0CAQ33575266-92CF326F-5126-4104-B92C-1B09B7B51D57Q34026770-8A79CE38-7ACE-4813-BE94-BB39041AE399Q34046604-EDAD2331-420D-494D-80D5-B14883C6B486Q34158974-C04D60B8-A5CF-498A-9F0D-2BE8F1C5887EQ34729776-7B08A80E-3A81-4C01-9A98-1E047B51FDBBQ36100952-5A8110DE-C34E-40D5-876A-823A5E604392Q37109324-76549167-8B7D-494B-B1AA-420B27EC3EB3Q37277121-4B84CBC0-359D-4E14-BF27-F21E38A0C8C9Q37349935-08AD87C5-1FBF-46D5-9325-8EAA9853D0E3Q37376013-4E63ED5E-D63F-4A3C-95B7-28ABA3FC1BB5Q37396817-D66A9613-9B78-4F4B-AF2F-CE90F7984513Q37799747-7A5568F7-890B-4060-8E89-B21372789E89Q39062888-4288BD6F-6F72-4526-92D0-D987CE7358ABQ39332703-3357108F-8271-4EC9-8363-CE097A30E6BDQ39839072-4183BB25-1866-4283-AF33-972B7818F3A5Q41834213-CAA499FC-36E3-4294-8485-83AB89991904Q42104930-E8CECE74-A4DB-4B48-A867-48FD2B25A149Q42316815-145186CB-1654-4552-B96C-0BEFC09B54D1Q43223889-84568448-D256-43BA-BAAB-158C4B194821Q43763736-7242C001-CAC6-48D7-89A8-1C94DD113251Q49333853-52F425BF-B469-4D2B-936E-FE3C7188F883Q52596153-283B1B9D-0ED8-43A5-8F9D-4F651EA95B04Q53693166-30B847DE-F663-4159-9E32-4713531A52A8
P2860
Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Expanding circle of inhibition ...... ell and antiangiogenic agents.
@en
Expanding circle of inhibition ...... ell and antiangiogenic agents.
@nl
type
label
Expanding circle of inhibition ...... ell and antiangiogenic agents.
@en
Expanding circle of inhibition ...... ell and antiangiogenic agents.
@nl
prefLabel
Expanding circle of inhibition ...... ell and antiangiogenic agents.
@en
Expanding circle of inhibition ...... ell and antiangiogenic agents.
@nl
P2093
P2860
P356
P1476
Expanding circle of inhibition ...... ell and antiangiogenic agents.
@en
P2093
Benjamin D Zeitlin
Isaac J Zeitlin
Jacques E Nör
P2860
P304
P356
10.1200/JCO.2007.15.7693
P407
P577
2008-09-01T00:00:00Z